Long-awaited treatment for hepatitis C virus decompensated cirrhosis

Kimura, Kiminori

doi:10.1007/s00535-018-01538-6

Cited by 1 publication

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, near results of Gentile et al, [11] the number of patients who switched from a decompensated to a compensated liver cirrhosis progressively increased during the observation from 45.5% at one-month treatment to 61.8% at last observation. Also were away from Kimura et al, [ [17] patients with decompensated cirrhosis who achieved SVR 12, approximately 25% of them showed improvement from CTP-B to CTP-A even in a short period of time. This difference in our opinion because of most of our CTP-B cases was (CTP-B7).…”

Section: Group I N=32mentioning

confidence: 98%

Outcome of Decompensated Hepatitis C Virus Cirrhotic Patients Treated with Direct Acting Antiviral Drugs

Ahmed

Zagloul

Gomaa

2020

Zagazig University Medical Journal

View full text Add to dashboard Cite

Background: All oral direct-acting antivirals (DAAs) effectively treat chronic hepatitis C infection (HCV) and widely used for patients with compensated cirrhosis. However, data regarding their safety and efficacy in patients with decompensated cirrhosis are insufficient . The aim of this work was to test efficacy, safety and outcome of DAAs in the treatment of decompensated HCV related cirrhotic patients (CTP-B). Methods: prospective study among 62 chronic HCV cirrhotic patients, divided into two groups. Group I(the study group) included 32 patients with CTP-B treated for 12 weeks by sofosbuvir (SOF) 400 mg once daily plus Daclatasvir (DCV) 60 mg once daily plus Ribavirin (RBV) with initial dose 600 mg /day), while group II (the control group) included 30 patients with CTP-A treated by (SOF 400 mg once daily + DCV 60 mg once daily +RBV dosed according to body weight) for 12 weeks. According to the National Committee for control of viral hepatitis (NCCVH). Follow up after end of treatment (EOT) for 24weeks so the total period of the study 36 weeks Results: cases achieved SVR in Group I: 93.75% and in group II:100%, Liver parameters were improved from baseline to 24 weeks after end of treatment. The most common adverse effects were anemia, no patients died by the end of the study, but one case 3.1% in group I stopped treatment due to severe complications. Conclusion: Treatment with DAAs in patients with CTP-B is effective and safe, but patients remain at risk of life-threatening complications as HCC and liver-related morbidity.

show abstract

Section: Group I N=32mentioning

confidence: 98%